000908 *ST景峰醫藥
按盤價 
4.140 +0.200 (+5.076%)
4.140 +0.200 (+5.076%) | 2024/06 - 中期 人民幣(K¥) | 與去年同期 比較 | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | 2020/12 人民幣(K¥) | ||
| 營業總收入 | 202,578 | -46.76% | 656,894 | 840,657 | 811,183 | 877,919 | |
| 減：營業總成本 | 228,133 | -39.93% | 793,080 | 891,127 | 1,172,830 | 1,526,877 | |
| 其中:營業成本 | 75,069 | -11.30% | 185,519 | 199,333 | 307,976 | 318,416 | |
| 財務費用 | 18,018 | -4.90% | 40,757 | 51,297 | 86,029 | 106,035 | |
| 資產減值損失 | (4,044) | -357.90% | (94,674) | (45,278) | (65,339) | (569,425) | |
| 公允價值變動收益 | -- | -- | 24,813 | 17,911 | 6,908 | -- | |
| 投資收益 | (419) | -42.79% | 4,096 | (4,090) | 249,321 | 223,109 | |
| 其中：對聯營企業和合營企業的投資收益 | (419) | -42.79% | (1,314) | (4,086) | (3,338) | (5,623) | |
| 營業利潤 | (19,616) | -234.45% | (172,910) | (68,317) | (135,892) | (1,123,605) | |
| 利潤總額 | (20,409) | -305.79% | (173,665) | (85,632) | (155,440) | (1,151,919) | |
| 減：所得稅費用 | 397 | -90.82% | 32,835 | 9,623 | 46,199 | 3,389 | |
| 淨利潤 | (20,805) | -471.87% | (206,500) | (95,255) | (201,639) | (1,155,308) | |
| 減：非控股權益 | 2,991 | -83.78% | 8,644 | 27,309 | (37,979) | (86,793) | |
| 股東淨利潤 | (23,796) | 85.25% | (215,144) | (122,564) | (163,660) | (1,068,515) | |
市場價值指標 | |||||||
| 每股收益 (元) * | -0.027 | 84.93% | -0.245 | -0.139 | -0.186 | -1.210 | |
| 每股派息 (元) * | -- | -- | -- | -- | -- | -- | |
| 每股淨資產 (元) * | -0.083 | -144.31% | -0.056 | 0.187 | 0.348 | 0.591 | |
| 審計意見 # | -- | 保留意见 | 保留意见 | 保留意见 | 带强调事项段的无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 報價延遲最少15分鐘，資料更新時間為 15/10/2024 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
